Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes

Published:2021-08-01 Issue:8 Volume:181 Page:1043
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Xie Yan¹²³,Bowe Benjamin¹²³,Gibson Andrew K.¹³,McGill Janet B.⁴,Maddukuri Geetha⁵,Al-Aly Ziyad¹³⁴⁵⁶

Affiliation:

1. Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri

2. Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, St Louis University, St Louis, Missouri

3. Veterans Research and Education Foundation of St Louis, St Louis, Missouri

4. Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri

5. Nephrology Section, Medicine Service, VA St Louis Health Care System, St Louis, Missouri

6. Institute for Public Health, Washington University in St Louis, St Louis, Missouri

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2781475/jamainternal_xie_2021_oi_210025_1631562025.50818.pdf

Reference60 articles.

1. Canagliflozin and cardiovascular and renal events in type 2 diabetes.;Neal;N Engl J Med,2017

2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.;Wiviott;N Engl J Med,2019

3. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.;Zinman;N Engl J Med,2015

4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.;Perkovic;N Engl J Med,2019

5. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.;Mosenzon;Lancet Diabetes Endocrinol,2019

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors;Communications Medicine;2024-09-11

2. Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years;Diabetes Research and Clinical Practice;2024-08

3. Therapeutic Applications of Plant and Nutraceutical-Based Compounds for the Management of Type 2 Diabetes Mellitus: A Narrative Review;Current Diabetes Reviews;2024-02

4. mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy;International Journal of Molecular Sciences;2023-10-11

5. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes;JAMA Network Open;2023-10-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3